paroxetine

• failure to achieve at least 50% symptom improvement (response), depression scale not named in the abstract

  decreases, RR 0.83, 99% CI 0.77-0.90

  Not recorded as a finding: antidepressant-response-rate node requires the rating scale (HDRS or MADRS) to be recorded; abstract never names the scale, and direction is a double negative

  Paroxetine was more effective than placebo, with fewer patients who did not experience improvement in symptoms of at least 50% (random effect RR 0.83, 99% CI 0.77-0.90).

  PMID:18227449 · one of two readings recorded this

• Patients who left the study because of side effects

  increases

  random effect RR 1.77, 95% CI 1.44-2.18

  PMID:18227449 · one of two readings recorded this

• Patients without improvement in symptoms of at least 50%

  decreases

  Paroxetine was more effective than placebo, with fewer patients who did not experience improvement in symptoms of at least 50% (random effect RR 0.83, 99% CI 0.77-0.90)

  PMID:18227449 · one of two readings recorded this

• proportion of patients leaving the study early for any reason

  no effect, RR 0.99, 99% CI 0.88-1.11

  Not recorded as a finding: no outcome node for all-cause early study discontinuation

  There was no difference between paroxetine and placebo in terms of the proportion of patients who left the study early for any reason (random effect relative risk [RR] 0.99, 99% confidence interval [CI] 0.88-1.11).

  PMID:18227449 · one of two readings recorded this

• proportion of patients who left the study early for any reason

  no effect, RR 0.99, 99% CI 0.88-1.11

  Not recorded as a finding: No node for all-cause study dropout

  There was no difference between paroxetine and placebo in terms of the proportion of patients who left the study early for any reason (random effect relative risk [RR] 0.99, 99% confidence interval [CI] 0.88-1.11).

  PMID:18227449 · one of two readings recorded this

• Proportion of patients who left the study early for any reason

  no effect

  random effect relative risk [RR] 0.99, 99% confidence interval [CI] 0.88-1.11

  PMID:18227449 · one of two readings recorded this

• suicidal tendencies

  increases, OR 2.55, 95% CI 1.17-5.54

  Not recorded as a finding: No node for suicidal ideation or behaviour events

  Significantly more patients in the paroxetine group than in the placebo group left their respective studies because of side effects (random effect RR 1.77, 95% CI 1.44-2.18) or experienced suicidal tendencies (odds ratio 2.55, 95% CI 1.17-5.54).

  PMID:18227449 · one of two readings recorded this

• Suicidal tendencies

  increases

  odds ratio 2.55, 95% CI 1.17-5.54

  PMID:18227449 · one of two readings recorded this

• Early response to treatment (patients who responded)

  decreases, n = 726

  OR: 2.39, 95% CI 1.42 to 4.02, NNTb = 8, 95% CI 5 to 14, at one to four weeks, 3 RCTs, 726 participants

  PMID:24696195 · one of two readings recorded this

• Early response to treatment (patients who responded)

  increases, n = 1375

  Odds Ratio (OR): 0.66, 95% Confidence Interval (CI) 0.50 to 0.87, number needed to treat to provide benefit (NNTb) = 16, 95% CI 10 to 50, at one to four weeks, 3 RCTs, 1375 participants

  PMID:24696195 · one of two readings recorded this

• patients who responded to treatment (primary outcome), and adverse events, paroxetine versus other antidepressants in major depression; abstract only

  Not recorded as a finding: the comparison was against another active treatment

  Paroxetine was less effective than citalopram in improving response to treatment (OR: 1.54, 95% CI 1.04 to 2.28, NNTb = 9, 95% CI 5 to 102, at six to 12 weeks, 1 RCT, 406 participants, moderate quality of evidence).

  PMID:24696195 · one of two readings recorded this

• Rate of adverse events

  decreases

  Paroxetine was associated with a lower rate of adverse events than amitriptyline, imipramine and older ADs as a class, but was less well tolerated than agomelatine and hypericum

  PMID:24696195 · one of two readings recorded this

• Response to treatment at acute, early or longer-term follow-up versus other antidepressants overall

  no effect

  We found no clear evidence that paroxetine was more or less effective compared with other antidepressants at increasing response to treatment at acute (six to 12 weeks), early (one to four weeks), or longer term follow-up (four to six months)

  PMID:24696195 · one of two readings recorded this

• Response to treatment at acute phase

  decreases, n = 406

  OR: 1.54, 95% CI 1.04 to 2.28, NNTb = 9, 95% CI 5 to 102, at six to 12 weeks, 1 RCT, 406 participants

  PMID:24696195 · one of two readings recorded this

• Tolerability

  increases

  Paroxetine was associated with a lower rate of adverse events than amitriptyline, imipramine and older ADs as a class, but was less well tolerated than agomelatine and hypericum

  PMID:24696195 · one of two readings recorded this

• change on the Hamilton Rating Scale for Depression (HRSD), paroxetine minus placebo, 27 placebo-controlled trials

  Not recorded as a finding: the direction is carried only as a signed number

  The weighted mean difference between paroxetine and placebo groups across all studies was 2.51 (95% CI: 2.06,2.96) points on the HRSD.

  PMID:25162656 · one of two readings recorded this

• change on the Hamilton Rating Scale for Depression (HRSD), paroxetine versus placebo, 27 placebo-controlled trials; also change on the Hamilton Rating Scale for Anxiety (HRSA), 12 trials

  Not recorded as a finding: the direction is carried only as a signed number

  The weighted mean difference between paroxetine and placebo groups across all studies was 2.51 (95% CI: 2.06,2.96) points on the HRSD.

  PMID:25162656 · one of two readings recorded this

• HRSA between-group difference significance

  decreases, p = 0.001

  The differences between groups easily met statistical significance for both the raw change scores on the HRSA (Z = 7.64, p<.001) and the standardized mean difference (Z = 7.52, p<.001)

  PMID:25162656 · one of two readings recorded this

• HRSA mean change and drug benefit (d)

  decreases

  29060/108 | Panic | 24.3 | 14.9 | 2.04 | [1.57, 2.51] | 58 | 23.5 | 10.0 | 1.62 | [1.21, 2.03] | 56 | 0.74 | [0.36, 1.12]

  PMID:25162656 · one of two readings recorded this

• HRSA mean change and drug benefit (d)

  no effect

  29060/120 | Panic | 18.9 | 8.4 | 0.95 | [0.77, 1.13] | 175 | 19.7 | 6.5 | 0.73 | [0.44, 1.02] | 60 | 0.21 | [−0.08, 0.50]

  PMID:25162656 · one of two readings recorded this

• HRSA mean change and drug benefit (d)

  decreases

  29060/187 | Panic | 10.1 | 1.10 | [0.87, 1.33] | 119 | 5.9 | 0.59 | [0.40, 0.79] | 122 | 0.44 | [0.19, 0.70]

  PMID:25162656 · one of two readings recorded this

• HRSA mean change and drug benefit (d)

  decreases

  29060/223 | Panic | 20.3 | 10.2 | 1.29 | [0.94, 1.64] | 61 | 18.7 | 5.6 | 0.76 | [0.48, 1.04] | 65 | 0.61 | [0.25, 0.97]

  PMID:25162656 · one of two readings recorded this

• HRSA mean change and drug benefit (d)

  no effect

  29060/494 | Panic | 21.9 | 10.0 | 1.08 | [0.84, 1.31] | 115 | 20.1 | 8.0 | 0.88 | [0.67, 1.09] | 124 | 0.22 | [−0.04, 0.47]

  PMID:25162656 · one of two readings recorded this

• HRSA mean change and drug benefit (d)

  decreases

  29060/495 | Panic | 20.5 | 9.4 | 1.03 | [0.79, 1.26] | 112 | 20.4 | 6.6 | 0.74 | [0.54, 0.94] | 129 | 0.31 | [0.06, 0.57]

  PMID:25162656 · one of two readings recorded this

• HRSA mean change and drug benefit (d)

  decreases

  29060/497 | Panic | 20.5 | 9.4 | 0.95 | [0.74, 1.16] | 128 | 20.2 | 6.8 | 0.75 | [0.55, 0.95] | 125 | 0.28 | [0.03, 0.52]

  PMID:25162656 · one of two readings recorded this

• HRSA mean change and drug benefit (d)

  no effect

  29060/637 | GAD | 26.0 | 12.4 | 1.15 | [0.96, 1.34] | 181 | 25.9 | 11.3 | 1.04 | [0.86, 1.22] | 183 | 0.10 | [−0.10, 0.31]

  PMID:25162656 · one of two readings recorded this

• HRSA mean change and drug benefit (d)

  decreases

  29060/641 | GAD | 23.5 | 12.3 | 1.48 | [1.33, 1.63] | 385 | 23.9 | 9.6 | 1.02 | [0.84, 1.20] | 180 | 0.32 | [0.14, 0.49]

  PMID:25162656 · one of two readings recorded this

• HRSA mean change and drug benefit (d)

  decreases

  29060/642 | GAD | 23.9 | 11.8 | 1.32 | [1.11, 1.54] | 161 | 23.6 | 9.5 | 1.06 | [0.86, 1.25] | 163 | 0.26 | [0.04, 0.48]

  PMID:25162656 · one of two readings recorded this

• HRSA mean change and drug benefit (d)

  no effect

  29060/791 | GAD | 24.4 | 11.9 | 1.60 | [1.37, 1.84] | 163 | 24.8 | 10.7 | 1.44 | [1.22, 1.67] | 162 | 0.17 | [−0.05, 0.38]

  PMID:25162656 · one of two readings recorded this

• HRSA mean change and drug benefit (d)

  no effect

  29060A/856 | GAD | 10.3 | 1.33 | [1.13, 1.53] | 177 | 9.5 | 1.23 | [1.04, 1.43] | 181 | 0.10 | [−0.10, 0.31]

  PMID:25162656 · one of two readings recorded this

• HRSA placebo change as share of paroxetine raw change

  The change in the placebo group duplicated 79% of the mean change score and 78% of the standardized mean difference in the paroxetine groups

  PMID:25162656 · one of two readings recorded this

• HRSA placebo change as share of paroxetine standardized mean difference

  The change in the placebo group duplicated 79% of the mean change score and 78% of the standardized mean difference in the paroxetine groups

  PMID:25162656 · one of two readings recorded this

• HRSA pre-post effect size by indication

  decreases

  GAD | 1.38 | [1.29, 1.46]

  PMID:25162656 · one of two readings recorded this

• HRSA pre-post effect size by indication

  decreases, p = 0.001

  Paroxetine | Panic | 1.07 | [0.98, 1.16] | 24.27 | <.001

  PMID:25162656 · one of two readings recorded this

• HRSA pre-post effect size by indication

  decreases

  GAD | 1.14 | [1.05, 1.22]

  PMID:25162656 · one of two readings recorded this

• HRSA pre-post effect size by indication

  decreases, p = 0.001

  Placebo | Panic | 0.78 | [0.69, 0.86] | 32.97 | <.001

  PMID:25162656 · one of two readings recorded this

• HRSA pre-post effect size by publication status

  decreases, p = 0.061

  Paroxetine | Published | 1.19 | [1.12, 1.27] | 3.52 |.061

  PMID:25162656 · one of two readings recorded this

• HRSA pre-post effect size by publication status

  decreases

  Unpublished | 1.32 | [1.21, 1.44]

  PMID:25162656 · one of two readings recorded this

• HRSA pre-post effect size by publication status

  decreases

  Placebo | Published | 0.86 | [0.79, 0.94] | 18.63 | <. 001

  PMID:25162656 · one of two readings recorded this

• HRSA pre-post effect size by publication status

  decreases

  Unpublished | 1.15 | [1.04, 1.25]

  PMID:25162656 · one of two readings recorded this

• HRSA pre-post effect size

  decreases

  d = 1.23 (95% CI: 1.17,1.30) for paroxetine

  PMID:25162656 · one of two readings recorded this

• HRSA pre-post effect size

  decreases

  d = 0.96 (95% CI: 0.90,1.02) for placebo

  PMID:25162656 · one of two readings recorded this

• HRSA raw change within paroxetine arm

  decreases

  raw change = 11.79 [95% CI: 11.29,12.30] points

  PMID:25162656 · one of two readings recorded this

• HRSA raw change within paroxetine arm

  decreases

  raw change = 10.06 [95% CI: 9.43,10.68] points

  PMID:25162656 · one of two readings recorded this

• HRSA raw change within placebo arm

  decreases

  raw change = 10.07 [95% CI: 9.49,10.64] points

  PMID:25162656 · one of two readings recorded this

• HRSA raw change within placebo arm

  decreases

  raw change = 7.17 [95% CI: 6.53,7.81] points

  PMID:25162656 · one of two readings recorded this

• HRSA raw drug-placebo difference

  decreases

  The mean drug-placebo difference was 2.31 (95% CI: 1.72,2.91) points on the HRSA with a mean effect size difference of d = 0.27 (95% CI: 0.20,0.33)

  PMID:25162656 · one of two readings recorded this

• HRSA raw drug-placebo difference

  decreases

  1.64 points (95% CI: 0.86,2.42) for generalized anxiety disorder

  PMID:25162656 · one of two readings recorded this

• HRSA raw drug-placebo difference

  decreases

  3.24 points (95% CI: 2.32,4.15) for panic disorder

  PMID:25162656 · one of two readings recorded this

• HRSA standardized drug-placebo difference

  decreases

  The mean drug-placebo difference was 2.31 (95% CI: 1.72,2.91) points on the HRSA with a mean effect size difference of d = 0.27 (95% CI: 0.20,0.33)

  PMID:25162656 · one of two readings recorded this

• HRSA standardized effect size by indication

  decreases

  GAD | 0.20 | [0.11, 0.29]

  PMID:25162656 · one of two readings recorded this

• HRSA standardized effect size by indication

  decreases

  Paroxetine - Placebo | Panic | 0.36 | [0.25, 0.46] | 5.09 |. 024

  PMID:25162656 · one of two readings recorded this

• HRSA standardized effect size by publication status

  decreases

  Paroxetine - Placebo | Published | 0.32 | [0.23, 0.40] | 3.90 |. 048

  PMID:25162656 · one of two readings recorded this

• HRSA standardized effect size by publication status

  decreases

  Unpublished | 0.17 | [0.06, 0.29]

  PMID:25162656 · one of two readings recorded this

• HRSA versus HRSD paroxetine-placebo effect size comparison

  no effect, p = 0.235

  the paroxetine-placebo effect size did not significantly differ between the HRSA and the HRSD (HRSA: d = 0.27 [95% CI: 0.20,0.33], HRSD: d = 0.32 [95% CI: 0.26,0.38], Q(1) = 1.41, p =.235)

  PMID:25162656 · one of two readings recorded this

• HRSA weighted mean change

  decreases

  The weighted mean change on the HRSA was 11.11 (95% CI: 10.72,11.50) points for paroxetine and 8.77 (95% 8.35,9.20) points for placebo

  PMID:25162656 · one of two readings recorded this

• HRSD mean change and drug benefit (d)

  decreases

  112810 | Post | 22.7 | 12.7 | 1.69 | [1.50, 1.89] | 241 | 22.6 | 10.4 | 1.28 | [1.07, 1.48] | 171 | 0.30 | [0.10, 0.49]

  PMID:25162656 · one of two readings recorded this

• HRSD mean change and drug benefit (d)

  no effect

  29060/01/001 | Pre | 28.0 | 13.5 | 1.66 | [0.99, 2.33] | 24 | 27.4 | 10.5 | 1.30 | [0.71, 1.89] | 24 | 0.37 | [−0.20, 0.94]

  PMID:25162656 · one of two readings recorded this

• HRSD mean change and drug benefit (d)

  decreases

  29060/02/001 | Pre | 26.6 | 12.3 | 1.27 | [0.89, 1.65] | 51 | 25.9 | 6.8 | 0.70 | [0.40, 1.01] | 53 | 0.57 | [0.18, 0.97]

  PMID:25162656 · one of two readings recorded this

• HRSD mean change and drug benefit (d)

  decreases

  29060/02/002 | Pre | 25.0 | 10.9 | 1.24 | [0.78, 1.69] | 36 | 24.9 | 5.8 | 0.65 | [0.27, 1.04] | 34 | 0.60 | [0.12, 1.08]

  PMID:25162656 · one of two readings recorded this

• HRSD mean change and drug benefit (d)

  no effect

  29060/02/003 | Pre | 28.6 | 9.7 | 0.93 | [0.50, 1.35] | 33 | 28.9 | 7.2 | 0.69 | [0.29, 1.08] | 33 | 0.24 | [−0.24, 0.73]

  PMID:25162656 · one of two readings recorded this

• HRSD mean change and drug benefit (d)

  decreases

  29060/02/004 | Pre | 28.9 | 12.7 | 1.87 | [1.29, 2.44] | 36 | 27.3 | 7.6 | 1.12 | [0.70, 1.54] | 38 | 0.76 | [0.29, 1.24]

  PMID:25162656 · one of two readings recorded this

• HRSD mean change and drug benefit (d)

  decreases

  29060/03/001 | Pre | 24.9 | 10.8 | 1.60 | [1.11, 2.09] | 40 | 24.8 | 4.7 | 0.69 | [0.33, 1.06] | 38 | 0.92 | [0.45, 1.39]

  PMID:25162656 · one of two readings recorded this

• HRSD mean change and drug benefit (d)

  no effect

  29060/03/002 | Pre | 24.9 | 8.0 | 1.14 | [0.72, 1.55] | 40 | 25.6 | 6.2 | 0.88 | [0.51, 1.26] | 40 | 0.26 | [−0.18, 0.70]

  PMID:25162656 · one of two readings recorded this

• HRSD mean change and drug benefit (d)

  no effect

  29060/03/003 | Pre | 25.7 | 9.9 | 1.18 | [0.76, 1.59] | 41 | 27.0 | 10.0 | 1.19 | [0.78, 1.60] | 42 | −0.01 | [−0.44, 0.42]

  PMID:25162656 · one of two readings recorded this

• HRSD mean change and drug benefit (d)

  decreases

  29060/03/004 | Pre | 27.6 | 10.4 | 1.32 | [0.86, 1.78] | 37 | 27.0 | 6.7 | 0.85 | [0.46, 1.24] | 37 | 0.48 | [0.02, 0.95]

  PMID:25162656 · one of two readings recorded this

• HRSD mean change and drug benefit (d)

  decreases

  29060/03/005 | Pre | 26.1 | 10.0 | 1.00 | [0.60, 1.39] | 40 | 26.8 | 4.1 | 0.41 | [0.08, 0.73] | 42 | 0.60 | [0.16, 1.05]

  PMID:25162656 · one of two readings recorded this

• HRSD mean change and drug benefit (d)

  decreases

  29060/03/006 | Pre | 29.7 | 9.1 | 1.10 | [0.69, 1.52] | 39 | 28.7 | 3.0 | 0.36 | [0.02, 0.71] | 37 | 0.76 | [0.29, 1.23]

  PMID:25162656 · one of two readings recorded this

• HRSD mean change and drug benefit (d)

  no effect

  29060/115 | Post | 10.6 | 1.23 | [1.07, 1.39] | 272 | 9.1 | 1.09 | [0.85, 1.33] | 113 | 0.18 | [−0.04, 0.40]

  PMID:25162656 · one of two readings recorded this

• HRSD mean change and drug benefit (d)

  decreases

  29060/128 | Post | 25.6 | 11.8 | 1.34 | [1.19, 1.48] | 350 | 25.7 | 9.1 | 1.05 | [0.84, 1.26] | 136 | 0.31 | [0.11, 0.51]

  PMID:25162656 · one of two readings recorded this

• HRSD mean change and drug benefit (d)

  decreases

  29060/251 | Post | 24.5 | 10.2 | 1.33 | [1.08, 1.57] | 120 | 24.4 | 8.3 | 1.07 | [0.85, 1.30] | 123 | 0.26 | [0.01, 0.51]

  PMID:25162656 · one of two readings recorded this

• HRSD mean change and drug benefit (d)

  decreases

  29060/327 | Post | 7.3 | 1.14 | [0.85, 1.42] | 79 | 4.8 | 0.75 | [0.51, 1.00] | 83 | 0.40 | [0.09, 0.71]

  PMID:25162656 · one of two readings recorded this

• HRSD mean change and drug benefit (d)

  no effect

  29060/329 | Post | 19.0 | 10.7 | 1.39 | [1.09, 1.68] | 90 | 19.0 | 9.1 | 1.16 | [0.89, 1.44] | 87 | 0.21 | [−0.08, 0.51]

  PMID:25162656 · one of two readings recorded this

• HRSD mean change and drug benefit (d)

  decreases

  29060/448 | Post | 23.2 | 11.9 | 1.45 | [1.25, 1.65] | 206 | 23.4 | 9.9 | 1.22 | [0.96, 1.48] | 101 | 0.25 | [0.01, 0.48]

  PMID:25162656 · one of two readings recorded this

• HRSD mean change and drug benefit (d)

  decreases

  29060/449 | Post | 23.8 | 12.7 | 1.54 | [1.35, 1.74] | 218 | 23.5 | 10.2 | 1.24 | [0.99, 1.49] | 110 | 0.30 | [0.07, 0.53]

  PMID:25162656 · one of two readings recorded this

• HRSD mean change and drug benefit (d)

  decreases

  29060/487 | Post | 22.2 | 12.2 | 1.68 | [1.46, 1.89] | 206 | 22.1 | 9.5 | 1.28 | [1.02, 1.54] | 107 | 0.37 | [0.14, 0.61]

  PMID:25162656 · one of two readings recorded this

• HRSD mean change and drug benefit (d)

  decreases

  29060/810 | Post | 23.3 | 12.0 | 1.68 | [1.50, 1.86] | 294 | 23.8 | 10.0 | 1.37 | [1.14, 1.60] | 142 | 0.28 | [0.08, 0.49]

  PMID:25162656 · one of two readings recorded this

• HRSD mean change and drug benefit (d)

  decreases

  29060/874 | Post | 22.5 | 11.4 | 1.42 | [1.27, 1.57] | 334 | 22.4 | 8.9 | 1.10 | [0.91, 1.28] | 178 | 0.32 | [0.14, 0.50]

  PMID:25162656 · one of two readings recorded this

• HRSD mean change and drug benefit (d)

  no effect

  PAR 07 | Pre | 30.5 | 13.1 | 1.20 | [0.37, 2.03] | 13 | 28.3 | 10.9 | 0.99 | [0.19, 1.79] | 12 | 0.22 | [−0.57, 1.00]

  PMID:25162656 · one of two readings recorded this

• HRSD mean change and drug benefit (d)

  no effect

  PAR 09 | Pre | 25.2 | 9.1 | 1.28 | [1.15, 1.41] | 403 | 24.5 | 8.2 | 1.14 | [0.78, 1.51] | 51 | 0.12 | [−0.17, 0.41]

  PMID:25162656 · one of two readings recorded this

• HRSD mean change and drug benefit (d)

  no effect

  UK 06 | Pre | 23.7 | 6.0 | 0.97 | [0.38, 1.57] | 19 | 24.2 | 6.2 | 0.83 | [0.31, 1.35] | 22 | −0.03 | [−0.64, 0.58]

  PMID:25162656 · one of two readings recorded this

• HRSD mean change and drug benefit (d)

  no effect

  UK 09 | Pre | 26.8 | 8.8 | 0.80 | [0.26, 1.35] | 20 | 25.5 | 4.5 | 0.49 | [0.01, 0.97] | 21 | 0.45 | [−0.17, 1.07]

  PMID:25162656 · one of two readings recorded this

• HRSD mean change and drug benefit (d)

  no effect

  UK 12 | Pre | 22.8 | 9.1 | 1.23 | [0.57, 1.88] | 19 | 22.3 | 6.7 | 0.86 | [0.00, 1.73] | 10 | 0.34 | [−0.43, 1.11]

  PMID:25162656 · one of two readings recorded this

• HRSD placebo change as share of paroxetine raw change

  The magnitude of change in the placebo group was equivalent to 76% of the paroxetine change scores on the HRSD and 74% of the standardized mean difference

  PMID:25162656 · one of two readings recorded this

• HRSD placebo change as share of paroxetine standardized mean difference

  The magnitude of change in the placebo group was equivalent to 76% of the paroxetine change scores on the HRSD and 74% of the standardized mean difference

  PMID:25162656 · one of two readings recorded this

• HRSD pre-post effect size by approval status

  decreases

  Post-Approval | 1.45 | [1.39, 1.50]

  PMID:25162656 · one of two readings recorded this

• HRSD pre-post effect size by approval status

  decreases, p = 0.001

  Paroxetine | Pre-Approval | 1.24 | [1.15, 1.33] | 14.43 | <.001

  PMID:25162656 · one of two readings recorded this

• HRSD pre-post effect size by approval status

  decreases

  Post-Approval | 1.14 | [1.07, 1.21]

  PMID:25162656 · one of two readings recorded this

• HRSD pre-post effect size by approval status

  decreases, p = 0.001

  Placebo | Pre-Approval | 0.77 | [0.67, 0.87] | 35.01 | <.001

  PMID:25162656 · one of two readings recorded this

• HRSD pre-post effect size by publication status

  decreases, p = 0.229

  Paroxetine | Published | 1.41 | [1.35, 1.48] | 1.45 |.229

  PMID:25162656 · one of two readings recorded this

• HRSD pre-post effect size by publication status

  decreases

  Unpublished | 1.35 | [1.28, 1.43]

  PMID:25162656 · one of two readings recorded this

• HRSD pre-post effect size by publication status

  decreases, p = 0.227

  Placebo | Published | 0.99 | [0.91, 1.07] | 1.46 |.227

  PMID:25162656 · one of two readings recorded this

• HRSD pre-post effect size by publication status

  decreases

  Unpublished | 1.06 | [0.98, 1.15]

  PMID:25162656 · one of two readings recorded this

• HRSD pre-post effect size

  decreases

  The mean pre-post effect size was 1.39 (95% CI: 1.34,1.44) for paroxetine

  PMID:25162656 · one of two readings recorded this

• HRSD pre-post effect size

  decreases

  the effect size for placebo (d = 1.03 [95% CI: 0.97,1.08])

  PMID:25162656 · one of two readings recorded this

• HRSD raw drug-placebo difference

  decreases

  The weighted mean difference between paroxetine and placebo groups across all studies was 2.51 (95% CI: 2.06,2.96) points on the HRSD

  PMID:25162656 · one of two readings recorded this

• HRSD standardized drug-placebo difference

  decreases

  The weighted mean effect size difference between the two groups was 0.32 (95% CI: 0.26,0.38)

  PMID:25162656 · one of two readings recorded this

• HRSD standardized drug-placebo difference

  decreases

  baseline severity of HRSD = 19 was d = 0.20 (95% CI: 0.03,0.36)

  PMID:25162656 · one of two readings recorded this

• HRSD standardized drug-placebo difference

  decreases

  d = 0.48 (95% CI: 0.29,0.68) at a baseline severity of HRSD = 30

  PMID:25162656 · one of two readings recorded this

• HRSD standardized effect size by approval status

  decreases

  Post-Approval | 0.29 | [0.22, 0.36]

  PMID:25162656 · one of two readings recorded this

• HRSD standardized effect size by approval status

  decreases, p = 0.071

  Paroxetine - Placebo | Pre-Approval | 0.41 | [0.30, 0.53] | 3.27 |.071

  PMID:25162656 · one of two readings recorded this

• HRSD standardized effect size by publication status

  decreases, p = 0.221

  Paroxetine - Placebo | Published | 0.36 | [0.27, 0.44] | 1.50 |.221

  PMID:25162656 · one of two readings recorded this

• HRSD standardized effect size by publication status

  decreases

  Unpublished | 0.28 | [0.20, 0.37]

  PMID:25162656 · one of two readings recorded this

• HRSD weighted mean change

  decreases

  The weighted mean change on the HRSD was 11.00 (95% CI: 10.74,11.26) points for paroxetine and 8.37 (95% CI: 8.02,8.72) points for placebo

  PMID:25162656 · one of two readings recorded this

• any major congenital malformations

  increases

  any major congenital malformations combined (pooled OR 1.23, 95% CI 1.10, 1.38; n = 15 studies)

  PMID:26613360 · one of two readings recorded this

• atrial septal defects

  increases

  atrial septal defects (pooled OR 2.38, 95% CI 1.14, 4.97; n = 4 studies)

  PMID:26613360 · one of two readings recorded this

• bulbus cordis anomalies and anomalies of cardiac septal closure

  increases

  specifically bulbus cordis anomalies and anomalies of cardiac septal closure (pooled OR 1.42, 95% CI 1.07, 1.89; n = 8 studies)

  PMID:26613360 · one of two readings recorded this

• major cardiac malformations

  increases

  major cardiac malformations (pooled OR 1.28, 95% CI 1.11, 1.47; n = 18 studies)

  PMID:26613360 · one of two readings recorded this

• right ventricular outflow track defect

  increases

  right ventricular outflow track defect (pooled OR 2.29, 95% CI 1.06, 4.93; n = 4 studies)

  PMID:26613360 · one of two readings recorded this

• IELT, paroxetine alone, Abu et al.

  increases

  The IELT significantly improved from 38.66 to 173.86 in the paroxetine group, while the placebo group showed almost no change

  PMID:30606186 · one of two readings recorded this

• IELT

  no effect, p = 0.24

  MD, 1.25; 95% [Cl], − 0.82 to 3.31; p = 0.24

  PMID:30606186 · one of two readings recorded this

• IELT

  no effect, p = 0.1

  the difference in IELT was not significant between the two groups at 1 month of treatment [MD, 0.05; 95% [Cl], − 0.01 to 0.11; p = 0.1]

  PMID:30606186 · one of two readings recorded this

• IELT

  increases, p = 0.001

  MD, 0.2; 95% [Cl], 0.08 to 0.32; p = 0.001

  PMID:30606186 · one of two readings recorded this

• IELT

  increases, p = 0.02

  was 0.54 in favour of paroxetine [95% Cl, 0.07 to 1.02; p = 0.02]

  PMID:30606186 · one of two readings recorded this

• IELT

  no effect, p = 0.72

  MD, 0.13; 95% [Cl], − 0.58 to 0.84, p = 0.72

  PMID:30606186 · one of two readings recorded this

• IELT

  no effect, p = 0.17

  between-group difference in IELT of − 0.59 [95% [Cl], − 1.45 to 0.26; p = 0.17]

  PMID:30606186 · one of two readings recorded this

• IELT

  no effect, p = 0.26

  MD, 0.19; 95% Cl, − 0.14 to 0.52; p = 0.26

  PMID:30606186 · one of two readings recorded this

• IELT

  no effect, p = 0.62

  Three RCTs provided evidence that suggested that the difference in IELT was not significant between the two groups [MD, 0.81; 95% [Cl], − 2.40 to 4.03; p = 0.62]

  PMID:30606186 · one of two readings recorded this

• IELT

  increases, p = 0.0003

  MD, − 0.40; 95% [Cl], − 0.62 to − 0.18; p = 0.0003

  PMID:30606186 · one of two readings recorded this

• IELT

  increases, p = 0.0004

  was − 0.79 in favour of the latter [95% Cl, − 1.23 to − 0.35; p = 0.0004]

  PMID:30606186 · one of two readings recorded this

• intra-vaginal ejaculatory latency time (IELT) in premature ejaculation, mean difference, paroxetine versus placebo and versus active comparators

  increases, MD 2.96 versus placebo, 95% CI 0.63 to 5.29, p = 0.01

  Not recorded as a finding: this platform holds no node for the endpoint

  The MD in IELT was 2.96, in favour of paroxetine [(random effect) 95% confidence interval [Cl], 0.63 to 5.29; p = 0.01].

  PMID:30606186 · one of two readings recorded this

• intra-vaginal ejaculatory latency time (IELT), pooled mean difference vs placebo

  increases, p = 0.01

  Not recorded as a finding: this platform holds no node for the endpoint

  Thus,based on 5 pooled RCTs, the men treated with paroxetine 20 mg for 4–12 weeks had significantly increased IELT compared with placebo (p = 0.01).

  PMID:30606186 · one of two readings recorded this

• intra-vaginal ejaculatory latency time (IELT)

  increases, p = 0.01

  The MD in IELT was 2.96, in favour of paroxetine [(random effect) 95% confidence interval [Cl], 0.63 to 5.29; p = 0.01]

  PMID:30606186 · one of two readings recorded this

• patients withdrawn after 6 months

  Wang et al. reported that 1.7 and 18.3% of patients withdrew from the study in the sildenafil and paroxetine groups, respectively, after 6 months

  PMID:30606186 · one of two readings recorded this

• patients withdrawn due to lack of efficacy or adverse effects

  Wang et al. reported that 18.3 and 36.7% of patients in the paroxetine and behaviour therapy groups, respectively, withdrew from the study due to lack of efficacy or adverse effects

  PMID:30606186 · one of two readings recorded this

• rate of occurrence of side effects, paroxetine versus combined behaviour therapy

  The rates of occurrence of side effects were 10.0 and 40% in the paroxetine and combined groups, respectively

  PMID:30606186 · one of two readings recorded this

• sexual satisfaction

  increases, p = 0.04

  Sexual satisfaction was also significantly higher with paroxetine than with dapoxetine (p = 0.04)

  PMID:30606186 · one of two readings recorded this

• side effects

  no effect, p = 0.73

  The pooled relative risk of 3 RCTs was 1.23 [RR (random effect) 95% Cl, 0.38 to 4.04; p = 0.73]

  PMID:30606186 · one of two readings recorded this

• side effects

  no effect, p = 0.07

  RR, 8.66; 95% Cl, 0.83 to 90.11; p = 0.07

  PMID:30606186 · one of two readings recorded this

• side effects

  increases

  significantly more side effects in the paroxetine group than in the dapoxetine group [RR, 2.50; 95% Cl, 1.16 to 5.38]

  PMID:30606186 · one of two readings recorded this

• side effects

  no effect, p = 0.52

  The relative risk of side effects between two groups pooled from 3 RCTs was 1.14 [RR (random effect) 95% Cl, 0.76 to 1.73; p = 0.52]

  PMID:30606186 · one of two readings recorded this

• side effects

  no effect, p = 0.98

  1.01 [RR (random effect)95% Cl, 0.44 to 2.33; p = 0.98]

  PMID:30606186 · one of two readings recorded this

• side effects

  no effect, p = 0.96

  p = 0.96) [RR, 1.04; 95% [Cl] 0.18 to 5.89]

  PMID:30606186 · one of two readings recorded this

• side effects

  no effect, p = 0.6

  RR, 0.80; 95% [Cl], 0.34 to 1.88; p = 0.6

  PMID:30606186 · one of two readings recorded this

• hot flush episodes, mean weekly reduction from baseline; nighttime awakenings, mean reduction per night

  decreases, MD -7.97 episodes/week [-10.51, -5.42]

  Not recorded as a finding: this platform holds no node for the endpoint

  Women who were treated with low-dose paroxetine had a significant reduction of hot flushes episodes (evaluated as mean weekly reduction from baseline) compared to placebo (mean difference −7.97 [−10.51, −5.42] episodes/week) (Table 2).

  PMID:31480427 · one of two readings recorded this

• hot flush episodes, mean weekly reduction from baseline

  decreases, MD -7.97 episodes/week, interval -10.51 to -5.42

  Not recorded as a finding: this platform holds no node for the endpoint

  Women who were treated with low-dose paroxetine had a significant reduction of hot flushes episodes (evaluated as mean weekly reduction from baseline) compared to placebo (mean difference −7.97 [−10.51, −5.42] episodes/week) (Table 2).

  PMID:31480427 · one of two readings recorded this

• hot flush episodes, mean weekly reduction from baseline

  decreases

  mean difference −7.97 [−10.51, −5.42] episodes/week

  PMID:31480427 · one of two readings recorded this

• hot flush episodes, mean weekly reduction from baseline

  decreases

  achieved reduction was −7.89 MD [−11.23, −4.81 CI] for patients with physiological menopause

  PMID:31480427 · one of two readings recorded this

• hot flush episodes, mean weekly reduction from baseline

  decreases

  −7.63 MD [−10.15, −5.56 CI] for women with surgical menopause

  PMID:31480427 · one of two readings recorded this

• mean nighttime awakenings reduction

  no effect

  −0.40 episodes/night MD [−1.38, 0.58 CI]

  PMID:31480427 · one of two readings recorded this

• baseline CGI-S score difference

  no effect, p = 0.99

  The baseline score had no significant difference (MD = −0.00, 95%CI −0.16 to 0.16, P =.99)

  PMID:32243377 · one of two readings recorded this

• baseline LSAS avoidance subscale difference

  no effect, p = 0.4

  avoidance: MD = 1.32, 95%CI −1.77 to 4.41, P =.40

  PMID:32243377 · one of two readings recorded this

• baseline LSAS fear subscale difference

  no effect, p = 0.27

  fear: MD = 0.90, 95%CI −0.71 to 2.50, P =.27

  PMID:32243377 · one of two readings recorded this

• baseline LSAS total score difference

  no effect, p = 0.54

  There was no significant difference in baseline LSAS total score between paroxetine and placebo groups (MD = 0.63, 95%CI −1.40 to 2.66, P =.54)

  PMID:32243377 · one of two readings recorded this

• baseline SADS total score difference

  no effect, p = 0.13

  The baseline score had no significant difference (MD = 0.49, 95%CI −0.14 to 1.11, P =.13)

  PMID:32243377 · one of two readings recorded this

• change in CGI-S score

  decreases, p = 0.00001

  Change in the CGI-S score was significantly greater in patients with SAD that received paroxetine compared to those received placebo (MD = 0.62, 95%CI 0.48–0.76, P <.00001)

  PMID:32243377 · one of two readings recorded this

• change in LSAS avoidance subscale score

  decreases, p = 0.00001

  avoidance: MD = 6.54, 95%CI 4.63–8.45, P <.00001

  PMID:32243377 · one of two readings recorded this

• change in LSAS fear subscale score

  decreases, p = 0.00001

  fear: MD = 6.76, 95%CI 4.89–8.62, P <.00001

  PMID:32243377 · one of two readings recorded this

• change in LSAS total score

  decreases, p = 0.00001

  MD = 13.46, 95%CI 10.59–16.32, P <.00001

  PMID:32243377 · one of two readings recorded this

• change in SADS total score

  decreases, p = 0.00001

  Change was significantly greater in patients with SAD that received paroxetine compared to those received placebo (MD = 3.22, 95%CI 2.31–4.13, P <.00001)

  PMID:32243377 · one of two readings recorded this

• change in SDS family item score

  decreases, p = 0.0006

  family item: MD = 0.53, 95%CI 0.22–0.83, P =.0006

  PMID:32243377 · one of two readings recorded this

• change in SDS social item score

  decreases, p = 0.00001

  social item: MD = 1.13, 95%CI 0.77–1.48, P <.00001

  PMID:32243377 · one of two readings recorded this

• change in SDS work item score

  decreases, p = 0.00001

  work item: MD = 0.93, 95%CI 0.56–1.29, P <.00001

  PMID:32243377 · one of two readings recorded this

• discontinuation rate due to adverse events

  increases, p = 0.00001

  Discontinuation rate due to AEs was higher in paroxetine group than placebo group (OR = 3.41, 95%CI 2.45–4.72, P <.00001)

  PMID:32243377 · one of two readings recorded this

• discontinuation rate due to any reason

  no effect, OR 1.06, 95% CI 0.81-1.39, p = 0.65

  Not recorded as a finding: No node for all-cause discontinuation

  There was no significant difference in discontinuation rate due to any reason between two groups (OR = 1.06, 95%CI 0.81–1.39, P =.65).

  PMID:32243377 · one of two readings recorded this

• discontinuation rate due to any reason

  no effect, p = 0.65

  There was no significant difference in discontinuation rate due to any reason between two groups (OR = 1.06, 95%CI 0.81–1.39, P =.65)

  PMID:32243377 · one of two readings recorded this

• discontinuation rate due to lack of efficacy

  decreases, p = 0.00001

  OR = 0.14, 95%CI 0.09–0.22, P <.00001

  PMID:32243377 · one of two readings recorded this

• incidence of any adverse event

  increases, OR = 1.83, 95%CI 1.43-2.35

  Not recorded as a finding: supplement-adverse-event-incidence is bound to oral or enteral supplements; adverse-reaction-incidence-ungraded requires attribution to study product

  The incidence of overall AEs (any AE) was reported in seven trials and the result was significantly higher in paroxetine than placebo group (OR = 1.83, 95%CI 1.43–2.35, P <.00001).

  PMID:32243377 · both readings recorded this

• incidence of any adverse event

  increases, p = 0.00001

  OR = 1.83, 95%CI 1.43–2.35, P <.00001

  PMID:32243377 · one of two readings recorded this

• Liebowitz Social Anxiety Scale total score, fear and avoidance subscales, mean change

  increases, fear MD = 6.76, 95%CI 4.89-8.62; avoidance MD = 6.54, 95%CI 4.63-8.45

  Not recorded as a finding: no outcome node for LSAS; the total-score sentence also misnames the comparator as duloxetine

  Changes in the fear and avoidance subscale of LSAS score were both significantly higher in the paroxetine group as compared with placebo group (fear: MD = 6.76, 95%CI 4.89–8.62, P <.00001; avoidance: MD = 6.54, 95%CI 4.63–8.45, P <.00001).

  PMID:32243377 · one of two readings recorded this

• publication bias (Egger's test)

  no effect, p = 0.662

  Visual inspection of the funnel plot as well as the results of Egger's test both revealed there was no significant publication bias (P =.662)

  PMID:32243377 · one of two readings recorded this

• remission rate

  increases, p = 0.00001

  OR = 3.14, 95%CI 2.25–4.39, P <.00001

  PMID:32243377 · one of two readings recorded this

• response and remission rates defined on CGI-I

  increases, response OR = 3.02, 95%CI 2.30-3.97

  Not recorded as a finding: antidepressant-response-rate node requires a depression rating scale 50% criterion; response here is CGI-I based

  Response rate was reported in 10 trials and the result was significantly greater in patients with SAD that received paroxetine compared to those received placebo (OR = 3.02, 95%CI 2.30–3.97, P <.00001).

  PMID:32243377 · one of two readings recorded this

• response rate defined as CGI-I score of 1 or 2

  increases, OR 3.02, 95% CI 2.30-3.97

  Not recorded as a finding: Antidepressant response node requires a depression rating scale criterion (HDRS or MADRS 50 percent reduction); this is a CGI-I social anxiety response, a different instrument

  Response rate was reported in 10 trials and the result was significantly greater in patients with SAD that received paroxetine compared to those received placebo (OR = 3.02, 95%CI 2.30–3.97, P <.00001).

  PMID:32243377 · one of two readings recorded this

• response rate

  increases, p = 0.00001

  OR = 3.02, 95%CI 2.30–3.97, P <.00001

  PMID:32243377 · one of two readings recorded this

• anti-PD efficacy, modified Webster score categories

  increases, OR 4.63, 95% CI 3.15 to 6.79

  Not recorded as a finding: No node for responder proportion on the modified Webster score

  Compared with control group, paroxetine therapy dramatically improved the anti-PD efficacy (OR 4.63, 95% CI 3.15 to 6.79, P <.00001).

  PMID:37653795 · one of two readings recorded this

• anti-PD efficacy

  increases, p = 0.00001

  Compared with control group, paroxetine therapy dramatically improved the anti-PD efficacy (OR 4.63, 95% CI 3.15 to 6.79, P <.00001)

  PMID:37653795 · one of two readings recorded this

• antidepressant response rate (observed pooled proportions)

  increases

  The observed response rate in paroxetine treatment group was 64.9% and that of control group was 36.1%

  PMID:37653795 · one of two readings recorded this

• antidepressant response

  increases, p = 0.00001

  Paroxetine therapy for dPD markedly increased the antidepressant response rate (OR 3.62, 95% CI 2.63 to 4.98, P <.00001)

  PMID:37653795 · one of two readings recorded this

• Hamilton anxiety rating scale (HAMA) score

  decreases, SMD -1.93, 95% CI -2.65 to -1.22

  Not recorded as a finding: no outcome node for HAMA

  Patients in paroxetine treatment group had lower HAMA score than that in control group (SMD -1.93, 95% CI -2.65 to -1.22, P <.00001).

  PMID:37653795 · both readings recorded this

• Hamilton anxiety rating scale score

  decreases, p = 0.00001

  Patients in paroxetine treatment group had lower HAMA score than that in control group (SMD -1.93, 95% CI -2.65 to -1.22, P <.00001)

  PMID:37653795 · one of two readings recorded this

• Hamilton depression rating scale score

  decreases, p = 0.00001

  The HAMD score showed significant decrease in the paroxetine treatment group compared to control group (SMD -2.14, 95% CI -2.73 to -1.56, P <.00001)

  PMID:37653795 · one of two readings recorded this

• number of any adverse events, per-trial ascertainment

  decreases, OR 0.42, 95% CI 0.31 to 0.57

  Not recorded as a finding: nodes for adverse events are bound to oral supplement or study-product attribution; not a clean match for a drug trial pooled count of any adverse event

  Compared with control group, paroxetine therapy for dPD decreased the number of any adverse events significantly (OR 0.42, 95% CI 0.31 to 0.57, P <.00001).

  PMID:37653795 · one of two readings recorded this

• number of any adverse events

  decreases, OR 0.42, 95% CI 0.31 to 0.57

  Not recorded as a finding: Adverse-event nodes require attribution to the study product or an oral supplement; this is any adverse event with trial-defined ascertainment

  Compared with control group, paroxetine therapy for dPD decreased the number of any adverse events significantly (OR 0.42, 95% CI 0.31 to 0.57, P <.00001).

  PMID:37653795 · one of two readings recorded this

• number of any adverse events

  decreases, p = 0.00001

  Compared with control group, paroxetine therapy for dPD decreased the number of any adverse events significantly (OR 0.42, 95% CI 0.31 to 0.57, P <.00001)

  PMID:37653795 · one of two readings recorded this

• total unified Parkinson's disease rating scale score

  decreases, p = 0.00001

  dPD patients in paroxetine treatment group had lower total UPDRS score than that in control group (SMD -2.02, 95% CI -2.48 to -1.55, P <.00001)

  PMID:37653795 · one of two readings recorded this

• total UPDRS score and anti-PD efficacy (modified Webster score categories)

  decreases

  Not recorded as a finding: no outcome node for UPDRS or Webster-based anti-PD efficacy

  Eighteen trials involving 1555 patients evaluated the total UPDRS score.

  PMID:37653795 · one of two readings recorded this

• 5D-ASC 3D-OAV total score

  no effect

  Paroxetine had no effect on 3D‐OAV total score ratings on the 5D‐ASC compared with placebo

  PMID:40022427 · one of two readings recorded this

• Duration of overall LSD effect (any drug effect)

  no effect

  The duration of the overall LSD effect (“any drug effect”) was similar after paroxetine (mean ± SD: 9.1 ± 2.3 h) and placebo (9.6 ± 2.4 h)

  PMID:40022427 · one of two readings recorded this

• LSD AUC∞ (geometric mean ratio)

  increases

  AUC∞ (ng·h/mL) | 15 (13–17) | 8.2–31 | 22 (19–25) | 11–48 | 1.47 (1.29–1.68)

  PMID:40022427 · one of two readings recorded this

• LSD AUC∞ (geometric mean ratio)

  increases

  AUC∞ (ng·h/mL) | 15 (11–19) | 9.1–26 | 20 (16–25) | 12–31 | 1.35 (1.11–1.62)

  PMID:40022427 · one of two readings recorded this

• LSD AUC∞ (geometric mean ratio)

  increases

  AUC∞ (ng·h/mL) | 12 (11–14) | 8.2–17 | 22 (17–28) | 11–48 | 1.76 (1.44–2.14)

  PMID:40022427 · one of two readings recorded this

• LSD AUC∞ (geometric mean ratio)

  no effect

  AUC∞ (ng·h/mL) | 28 (21–36) | 25–31 | 28 (24–34) | 26–30 | 1.02 (0.84–1.24)

  PMID:40022427 · one of two readings recorded this

• LSD CL/F (geometric mean ratio)

  decreases

  CL/F (L/h) | 6.8 (5.9–8.0) | 3.2–12 | 4.6 (4.0–5.4) | 2.1–9.2 | 0.68 (0.60–0.77)

  PMID:40022427 · one of two readings recorded this

• LSD Cmax (geometric mean ratio)

  increases

  C max (ng/mL) | 2.0 (1.7–2.3) | 1.2–4.5 | 2.8 (2.5–3.2) | 1.9–5.4 | 1.41 (1.24–1.60)

  PMID:40022427 · one of two readings recorded this

• LSD Cmax (geometric mean ratio)

  increases

  C max (ng/mL) | 2.0 (1.5–2.6) | 1.2–4.5 | 2.6 (2.1–3.2) | 1.9–4.6 | 1.32 (1.08–1.60)

  PMID:40022427 · one of two readings recorded this

• LSD Cmax (geometric mean ratio)

  increases

  C max (ng/mL) | 1.8 (1.6–2.1) | 1.3–2.4 | 3.0 (2.4–3.7) | 2.0–5.4 | 1.62 (1.32–1.99)

  PMID:40022427 · one of two readings recorded this

• LSD Cmax (geometric mean ratio)

  no effect

  C max (ng/mL) | 3.0 (1.8–5.0) | 2.6–3.8 | 3.2 (1.5–6.5) | 2.3–4.1 | 1.05 (0.82–1.33)

  PMID:40022427 · one of two readings recorded this

• LSD half-life (geometric mean ratio)

  increases

  t 1/2 (h) | 3.5 (3.2–3.8) | 2.6–6.1 | 4.3 (3.9–4.8) | 3.0–9.3 | 1.24 (1.17–1.31)

  PMID:40022427 · one of two readings recorded this

• LSD half-life (geometric mean ratio)

  increases

  t 1/2 (h) | 3.5 (3.0–4.0) | 2.8–4.7 | 4.1 (3.7–4.7) | 3.4–5.9 | 1.19 (1.06–1.34)

  PMID:40022427 · one of two readings recorded this

• LSD half-life (geometric mean ratio)

  increases

  t 1/2 (h) | 3.3 (3.0–3.5) | 2.6–3.9 | 4.2 (3.7–4.7) | 3.0–5.6 | 1.28 (1.20–1.36)

  PMID:40022427 · one of two readings recorded this

• LSD half-life (geometric mean ratio)

  no effect

  t 1/2 (h) | 4.7 (2.6–8.5) | 3.9–6.1 | 5.8 (2.1–16) | 4.4–9.3 | 1.23 (0.87–1.74)

  PMID:40022427 · one of two readings recorded this

• LSD-induced elevation of heart rate

  decreases

  Paroxetine significantly reduced LSD‐induced elevations of heart rate but not blood pressure compared with placebo

  PMID:40022427 · one of two readings recorded this

• LSD-induced nausea VAS (peak and overall)

  decreases

  peak and overall nausea were significantly lower after paroxetine compared with placebo

  PMID:40022427 · one of two readings recorded this

• LSD-induced subjective effects on single-item VAS (bad drug effect, anxiety, nausea), with no effect on good drug effect; 5D-ASC 3D-OAV total score

  decreases

  Not recorded as a finding: no outcome node for acute psychedelic subjective-effect VAS items or 5D-ASC; also the study is a drug-interaction design with LSD given in both conditions

  Consistent with our hypotheses, paroxetine significantly reduced LSD‐induced single‐item VAS ratings of “bad drug effect” and “anxiety,” while having no effect on any other items, including “good drug effect” (Table

  PMID:40022427 · one of two readings recorded this

• LSD-induced VAS ratings of bad drug effect and anxiety

  decreases

  paroxetine significantly reduced LSD‐induced single‐item VAS ratings of “bad drug effect” and “anxiety,” while having no effect on any other items, including “good drug effect”

  PMID:40022427 · one of two readings recorded this

• LSD Tmax (geometric mean ratio)

  no effect

  T max (h) | 1.8 (1.4–2.3) | 0.50–4.0 | 1.7 (1.3–2.1) | 0.50–3.5 | 0.92 (0.75–1.13)

  PMID:40022427 · one of two readings recorded this

• LSD Vz/F (geometric mean ratio)

  decreases

  V z/ F (L) | 34 (31–38) | 18–56 | 29 (25–33) | 14–48 | 0.84 (0.74–0.95)

  PMID:40022427 · one of two readings recorded this

• O-H-LSD AUC∞ (geometric mean ratio)

  increases

  AUC∞ (ng·h/mL) | 2.5 (2.2–2.8) | 1.6–4.4 | 3.6 (3.3–3.9) | 2.4–5.3 | 1.44 (1.31–1.58)

  PMID:40022427 · one of two readings recorded this

• O-H-LSD AUC∞ (geometric mean ratio)

  increases

  AUC∞ (ng·h/mL) | 2.7 (2.2–3.5) | 1.7–4.4 | 3.7 (3.1–4.5) | 2.5–5.3 | 1.35 (1.17–1.56)

  PMID:40022427 · one of two readings recorded this

The whole record — 307 rows